Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 Meeting Abstract
| Authors: | Makker, V.; Colombo, N.; Santin, A.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Ray-Coquard, I. L.; Kim, Y. M.; Guerra, E. M.; Huang, J.; Barresi, G.; McKenzie, J.; Lorusso, D. |
| Abstract Title: | Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775 |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680301644 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.5587 |
| Notes: | Meeting Abstract: 5587 -- Meeting also held virtually -- Source: Wos |
